Send to

Choose Destination
Curr Res Transl Med. 2019 Aug;67(3):79-88. doi: 10.1016/j.retram.2019.05.002. Epub 2019 Jun 8.

An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.

Author information

Dept. of Haematology, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland. Electronic address:
EBMT Data Office, 2300 Leiden, the Netherlands.
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
CHU de Lille, LIRIC, INSERM U995, Université de Lille, 59000, Lille, France.



Two chimeric antigen receptor (CAR) T-cell therapies - Tisagenlecleucel (Kymriah) and Axicabtagene ciloleucel (Yescarta) - have been approved for commercial use. In order to inform forthcoming EBMT guidelines on the management of adults and children undergoing autologous CAR T-cell therapy, we undertook a survey of experienced clinicians.


An online survey with a dual focus on (1) 'real world' patient eligibility criteria and (2) models of care for patient follow-up was sent to experienced physicians.


There were 41 respondents (10 countries) and 93% worked in FACT-JACIE-accredited transplant centres. Most felt that a history of malignancy (57%), prior allo-HCT for B-NHL (78%-81%) and prior treatment with anti-CD19/CD3 BiTE antibodies (76%-86%) do not constitute contra-indications to CAR T therapy. Clinicians were divided as to whether CNS involvement represented an exclusion criterion. There was agreement that patients with viral infections (HIV, Hepatitis B or Hepatitis C) are not eligible. There is no common model of care for long-term follow-up. Most respondents believed that patients should attend the hospital two (43%) to three (33%) times weekly during the first month following discharge. A majority (69%) of respondents work in centres where there is an MDT meeting with a specific focus on follow-up following CAR T Therapy. Follow-up care is currently delivered either in HCT or haematology-oncology outpatient clinics.


The responses reveal wide variation in perceived patient eligibility criteria and highlight the need for consensus guidelines. The findings also illustrate the embryonic nature of current follow-up arrangements.


CAR T; CAR T-cells; Long-term follow-up; Patient eligibility; Patient selection

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center